LTGO

13.0501.44%
NF

Nima Farzan

Executive Officer

Mr. Nima Farzan, M.B.A. had been Chief Executive Officer and Director of Latigo Biotherapeutics Inc. since July 2024 until November 03, 2026 and served as its President until November 03, 2026 and will continue as an employee of the Company through January 1, 2027. He served as President and Chief Executive Officer at Kinnate Biopharma Inc. from March 2020 to April 3, 2024 and as a Member of Board of Directors from March 2020 to April 3, 2024. Mr. Farzan had been the Chief Executive Officer at PaxVax, Inc. from April 2015 to October 2018 and served as its President. Mr. Farzan has also served as an Executive in Residence at Foresite Capital, a venture capital fund, from February 2020 to March 2020. From October 2018 to March 2020, Mr. Farzan worked as an advisor to various life sciences companies, including Emergent BioSolutions Inc from October 2018 to February 2020. and MODA Pharmaceuticals. Mr. Farzan has been Independent Director of Keros Therapeutics, Inc. since March 2020. He served as the Chief Operating Officer of PaxVax, Inc. from September 2011 to May 2015. He served at Novartis AG for many years in positions of increasing responsibility in pharmaceutical marketing, sales and development in both US and global positions from 2003 to 2011. He served as Vice President of Marketing at Novartis Vaccines USA, where he was responsible for marketing, market access, pricing and key account sales and also helped launch multiple new vaccines. Mr. Farzan worked in marketing and business development at DoubleTwist, Inc from 1997 to 1999. He served as Member of Advisory Board at Darmiyan, Inc. He served as a Consultant of The Boston Consulting Group. Mr. Farzan has been a Director of PaxVax, Inc. since January 21, 2015. Mr. Farzan has an M.B.A. from Harvard Business School and BA in Human Biology from Stanford University.

Positions